Biotech Values

[DewDiligence]

MNTA’s new Copaxone patent makes it unlikely, IMO, that MYL will be able to get FDA approval for its own generic Copaxone without infringing MNTA’s patent.

Which is not to imply that MYL’s Copaxone program, which is openly using Natco’s Copaxone knockoff from India, was ever likely to succeed.